Reportlinker Adds Endometrial Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2017
NEW YORK, April 14, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Endometrial Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Endometrial Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Summary
GlobalData, the industry analysis specialist, has released its new report, "Endometrial Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2017". The report is an essential source of information and analysis on the global Endometrial Cancer Therapeutics market. The report identifies the key trends shaping and driving the global Endometrial Cancer Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Endometrial Cancer Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts
Scope
The report provides information on the key drivers and challenges of the Endometrial Cancer Therapeutics market. Its Scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Endometrial Cancer Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Endometrial Cancer Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Endometrial Cancer Therapeutics therapeutics market.
- Analysis of key recent licensing and partnership agreements in Endometrial Cancer Therapeutics market
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Endometrial Cancer Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Endometrial Cancer Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What's the next big thing in the global Endometrial Cancer Therapeutics market landscape? – Identify, understand and capitalize.
1 Table of contents
1 Table of contents 2
1.1 List of Tables 4
1.2 List of Figures 5
2 Endometrial Cancer Therapeutics: Introduction 6
2.1 Overview 6
2.2 Epidemiology 6
2.3 Etiology 6
2.4 Symptoms 6
2.5 Diagnosis 7
2.6 Prognosis 7
2.7 Pathology 7
2.8 Staging 8
2.9 Treatment 10
2.10 GlobalData Pipeline Report Guidance 12
3 Endometrial Cancer Therapeutics: Market Characterization 13
3.1 Endometrial Cancer Therapeutics Market Size (2005-2010) – Global 13
3.2 Endometrial Cancer Therapeutics Market Forecast (2010-2017) – Global 14
3.3 Endometrial Cancer Therapeutics Market Size (2005-2010) – The US 15
3.4 Endometrial Cancer Therapeutics Market Forecast (2010-2017) – The US 16
3.5 Endometrial Cancer Therapeutics Market Size (2005-2010) – France 17
3.6 Endometrial Cancer Therapeutics Market Forecast (2010-2017) – France 18
3.7 Endometrial Cancer Therapeutics Market Size (2005-2010) – Germany 19
3.8 Endometrial Cancer Therapeutics Market Forecast (2010-2017) – Germany 20
3.9 Endometrial Cancer Therapeutics Market Size (2005-2010) – Italy 21
3.10 Endometrial Cancer Therapeutics Market Forecast (2010-2017) – Italy 22
3.11 Endometrial Cancer Therapeutics Market Size (2005-2010) – Spain 23
3.12 Endometrial Cancer Therapeutics Market Forecast (2010-2017) – Spain 24
3.13 Endometrial Cancer Therapeutics Market Size (2005-2010) – The UK 25
3.14 Endometrial Cancer Therapeutics Market Forecast (2010-2017) – The UK 26
3.15 Endometrial Cancer Therapeutics Market Size (2005-2010) – Japan 27
3.16 Endometrial Cancer Therapeutics Market Forecast (2010-2017) – Japan 28
3.17 Drivers and Barriers 29
3.17.1 Drivers for the Endometrial Cancer Therapeutics Market 29
3.17.2 Barriers for the Endometrial Cancer Therapeutics Market 29
3.18 Opportunity and Unmet Need Analysis 30
3.19 Key Takeaway 30
4 Endometrial Cancer Therapeutics: Competitive Assessment 31
4.1 Overview 31
4.1.1 Strategic Competitor Assessment 31
4.2 Product Profiles for the Major Marketed Products in the Endometrial Cancer Therapeutics Market 32
4.2.1 Carboplatin plus Paclitaxel 32
4.2.2 Cisplatin Plus Doxorubicin 32
4.2.3 Cisplatin + Doxorubicin + Paclitaxel 33
4.2.4 Liposomal doxorubicin 34
4.2.5 Hormone therapies 34
4.3 Key Takeaway 34
5 Endometrial Cancer Therapeutics: Pipeline Assessment 35
5.1 Overview 35
5.2 Strategic Pipeline Assessment 35
5.3 Endometrial Cancer Therapeutics Pipeline – Pipeline by Clinical Phases of Development 35
5.4 Pipeline Analysis by Phase of Development 36
5.4.1 Endometrial Cancer Therapeutics – Phase III Pipeline 36
5.4.2 Endometrial Cancer Therapeutics – Phase II Pipeline 36
5.4.3 Endometrial Cancer Therapeutics – Phase I Pipeline 37
5.4.4 Endometrial Cancer Therapeutics – Preclinical Pipeline 37
5.5 Technology Trends Analytical Framework 38
5.6 Pipeline by Mechanism of Action 39
5.7 Endometrial Cancer Therapeutics – Promising Drugs Under Clinical Development 40
5.8 Molecule Profile for Promising Drugs Under Clinical Development 40
5.8.1 Ixempra 40
5.9 Key Takeaway 40
6 Endometrial Cancer Therapeutics: Clinical Trials Mapping 41
6.1 Clinical Trials by Region/Country (US, EU5 and Japan) 41
6.2 Clinical Trials by Phase 42
6.3 Clinical Trials by Trial Status 43
6.4 Overall Sponsors 44
6.5 Prominent Sponsors 45
6.6 Top Companies Participating in Therapeutics Clinical Trials 46
7 Endometrial Cancer Therapeutics: Strategic Assessment 48
7.1 Key Events Impacting the Future Market 48
7.2 Endometrial Cancer Therapeutics – Implications for Future Market Competition 49
8 Endometrial Cancer Therapeutics: Future Players 50
8.1 Introduction 50
8.2 Company Profiles 51
8.2.1 Bristol-Myers Squibb Company 51
8.2.2 AEterna Zentaris Inc 59
8.2.3 Ariad Pharmaceuticals Inc 62
8.2.4 Eisai Co., Ltd 64
8.2.5 EntreMed, Inc. 69
8.2.6 Exelixis, Inc. 71
8.2.7 Ipsen S.A. (Ipsen) 74
8.2.8 Merck & Co 77
8.2.9 Novartis AG 84
8.2.10 PharmaMar, S.A (Subsidiary of Zeltia, S.A.) 90
8.2.11 Sanofi-Aventis 91
8.3 Details of Other Companies in the Pipeline 95
9 Endometrial Cancer Therapeutics: Deals 96
10 Endometrial Cancer Therapeutics: Appendix 97
10.1 Market Definitions 97
10.2 Abbrevations 97
10.3 Research Methodology 98
10.3.1 Coverage 98
10.3.2 Secondary Research 98
10.3.3 Forecasting 98
10.3.4 Primary Research 101
10.3.5 Expert Panel Validation 102
10.4 Contact Us 102
10.5 Disclaimer 102
10.6 Bibliography 103
1.1 List of Tables
Table 1: Endometrial Cancer Therapeutics Market, Staging – TNM Classification 8
Table 2: Endometrial Cancer Therapeutics Market, – Staging Terminology 9
Table 3: Endometrial Cancer Therapeutics Market, Global, Revenue ($m), 2005–2010 13
Table 4: Endometrial Cancer Therapeutics Market, Global, Forecast ($m), 2010–2017 14
Table 5: Endometrial Cancer Therapeutics Market, the US, Revenue ($m), 2005–2010 15
Table 6: Endometrial Cancer Therapeutics Market, the US, Forecast ($m), 2010–2017 16
Table 7: Endometrial Cancer Therapeutics Market, France, Revenue ($m), 2005–2010 17
Table 8: Endometrial Cancer Therapeutics Market, France, Forecast ($m), 2010–2017 18
Table 9: Endometrial Cancer Therapeutics Market, Germany, Revenue ($m), 2005–2010 19
Table 10: Endometrial Cancer Therapeutics Market, Germany, Forecast ($m), 2010–2017 20
Table 11: Endometrial Cancer Therapeutics Market, Italy, Revenue ($m), 2005–2010 21
Table 12: Endometrial Cancer Therapeutics Market, Italy, Forecast ($m), 2010–2017 22
Table 13: Endometrial Cancer Therapeutics Market, Spain, Revenue ($m), 2005–2010 23
Table 14: Endometrial Cancer Therapeutics Market, Spain, Forecast ($m), 2010–2017 24
Table 15: Endometrial Cancer Therapeutics Market, the UK, Revenue ($m), 2005–2010 25
Table 16: Endometrial Cancer Therapeutics Market, the UK, Forecast ($m), 2010–2017 26
Table 17: Endometrial Cancer Therapeutics Market, Japan, Revenue ($m), 2005–2010 27
Table 18: Endometrial Cancer Therapeutics Market, Japan, Forecast ($m), 2010–2017 28
Table 19: Endometrial Cancer Therapeutics Market, Therapeutics – Phase III Pipeline, Feb 2011 36
Table 20: Endometrial Cancer Therapeutics Market, Therapeutics – Phase II Pipeline, Feb 2011 36
Table 21: Endometrial Cancer Therapeutics Market, Therapeutics – Phase I Pipeline, Feb 2011 37
Table 22: Endometrial Cancer Therapeutics Market, Therapeutics – Preclinical Pipeline, Feb 2011 37
Table 23: Endometrial Cancer Therapeutics Market, Therapeutics – Most Promising Drugs Under Clinical Development, 2011 40
Table 24: Endometrial Cancer Therapeutics Market, Therapeutics – Clinical Trials by Country, 2010 41
Table 25: Endometrial Cancer Therapeutics Market, Therapeutics – Clinical Trials by Phase, 2010 42
Table 26: Endometrial Cancer Therapeutics Market, Therapeutics – Clinical Trials by Status, 2010 43
Table 27: Endometrial Cancer Therapeutics Market, Therapeutics – Prominent Sponsors, 2010 45
Table 28: Endometrial Cancer Therapeutics Market, Therapeutics – Top Companies Participating in Therapeutics Clinical Trials, 2010 47
Table 29: Bristol-Myers Squibb Company, Pipeline, 2011 52
Table 30: Bristol-Myers Squibb Company Deals, 2009-2010 55
Table 31: AEterna Zentaris Inc, Oncology Pipeline, 2010 60
Table 32: AEterna Zentaris, Deals, 2009-2010 60
Table 33: Ariad Pharmaceuticals Inc, Oncology Pipeline, 2011 63
Table 34: Ariad Pharmaceuticals Inc, Deals, 2009-2010 63
Table 35: Eisai Co. Ltd, Oncology Pipeline, 2011 65
Table 36: Eisai Co. Ltd, Deals, 2009-2011 66
Table 37: EntreMed Inc, Oncology Pipeline, 2011 70
Table 38: EntreMed Inc, Deals, 2010 70
Table 39: Exelixis Inc., Pipeline, 2011 72
Table 40: Exelixis Inc., Deals, 2009-2010 73
Table 41: Ipsen S.A, Pipeline, 2011 75
Table 42: Ipsen S.A, Deals, 2009-2010 75
Table 43: Merck & Co., Inc, Oncology Pipeline, 2011 78
Table 44: Merck & Co., Inc, Deals, 2009-2010 78
Table 45: Novartis – Oncology Pipeline, 2010 86
Table 46: Novartis AG, Deals 87
Table 47: PharmaMar, S.A, Deals, 2009 90
Table 48: Sanofi-Aventis Oncology Pipeline, 2011 92
Table 49: Sanofi-Aventis Key Deals, 2010-2011 93
Table 50: Details of Other Companies in the Pipeline 95
Table 51: Endometrial Cancer Therapeutics Market, Therapeutics, Global, Deals, 2010 96
1.2 List of Figures
Figure 1: Endometrial Cancer Therapeutics Market, – Surgical Procedures 10
Figure 2: Endometrial Cancer Therapeutics Market, Global, Revenue ($m), 2005–2010 13
Figure 3: Endometrial Cancer Therapeutics Market, Global, Forecast ($m), 2010–2017 14
Figure 4: Endometrial Cancer Therapeutics Market, the US, Revenue ($m), 2005–2010 15
Figure 5: Endometrial Cancer Therapeutics Market, the US, Forecast ($m), 2010–2017 16
Figure 6: Endometrial Cancer Therapeutics Market, France, Revenue ($m), 2005–2010 17
Figure 7: Endometrial Cancer Therapeutics Market, France, Forecast ($m), 2010–2017 18
Figure 8: Endometrial Cancer Therapeutics Market, Germany, Revenue ($m), 2005–2010 19
Figure 9: Endometrial Cancer Therapeutics Market, Germany, Forecast ($m), 2010–2017 20
Figure 10: Endometrial Cancer Therapeutics Market, Italy, Revenue ($m), 2005–2010 21
Figure 11: Endometrial Cancer Therapeutics Market, Italy, Forecast ($m), 2010–2017 22
Figure 12: Endometrial Cancer Therapeutics Market, Spain, Revenue ($m), 2005–2010 23
Figure 13: Endometrial Cancer Therapeutics Market, Spain, Forecast ($m), 2010–2017 24
Figure 14: Endometrial Cancer Therapeutics Market, the UK, Revenue ($m), 2005–2010 25
Figure 15: Endometrial Cancer Therapeutics Market, the UK, Forecast ($m), 2010–2017 26
Figure 16: Endometrial Cancer Therapeutics Market, Japan, Revenue ($m), 2005–2010 27
Figure 17: Endometrial Cancer Therapeutics Market, Japan, Forecast ($m), 2010–2017 28
Figure 18: Opportunity and Unmet Need in the Endometrial Cancer Therapeutics Market 30
Figure 19: Endometrial Cancer Therapeutics Market, Therapeutics – Strategic Competitor Assessment, 2010 31
Figure 20: Endometrial Cancer Therapeutics Market, Therapeutics – Pipeline by Phase of Clinical Development, Feb 2011 35
Figure 21: Endometrial Cancer Therapeutics Market, Therapeutics – Technology Trends Analytics Framework, Feb 2011 38
Figure 22: Endometrial Cancer Therapeutics Market, Therapeutics – Technology Trends Analytics Framework – Description, Feb 2011 38
Figure 23: Endometrial Cancer Therapeutics Market, Therapeutics – Pipeline by Mechanism of Action, 2011 39
Figure 24: Endometrial Cancer Therapeutics Market, Therapeutics – Clinical Trials by Country, 2010 41
Figure 25: Endometrial Cancer Therapeutics Market, Therapeutics – Clinical Trials by Phase, 2010 42
Figure 26: Endometrial Cancer Therapeutics Market, Therapeutics – Clinical Trials by Status, 2010 43
Figure 27: Endometrial Cancer Therapeutics Market, Therapeutics – Overall Sponsors, 2010 44
Figure 28: Endometrial Cancer Therapeutics Market, Therapeutics – Prominent Sponsors, 2010 45
Figure 29: Endometrial Cancer Therapeutics Market, Therapeutics – Top Companies Participating in Therapeutics Clinical Trials, 2010 46
Figure 30: Endometrial Cancer Therapeutics Market, Therapeutics, Drivers and Restraints, 2010 48
Figure 31: Endometrial Cancer Therapeutics Market, Therapeutics – Implications for Future Market Competition, 2010 49
Figure 32: Endometrial Cancer Therapeutics Market, Therapeutics – Pipeline by Company, 2010 50
Figure 33: GlobalData Market Forecasting Model 101Bristol-Myers Squibb Company
AEterna Zentaris Inc
Ariad Pharmaceuticals Inc
Eisai Co., Ltd
EntreMed, Inc.
Exelixis, Inc.
Ipsen S.A. (Ipsen)
Merck & Co
Novartis AG
PharmaMar, S.A (Subsidiary of Zeltia, S.A.)
Sanofi-Aventis
To order this report:
: Endometrial Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Check our Company Profile, SWOT and Revenue Analysis!
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article